Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282432 · ClinicalTrials.gov registry record
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
A clinical trial of Leukocyte Adhesion Deficiency, sponsored by Rocket Pharmaceuticals.
- Active
- Registry status
- 9
- Enrollment target
- 3
- Study locations
NCT06282432: Active study of Leukocyte Adhesion Deficiency, sponsored by Rocket Pharmaceuticals.
NCT06282432 is a study of Leukocyte Adhesion Deficiency that is active but no longer recruiting, run by Rocket Pharmaceuticals. The registered enrollment target is 9 participants. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06282432, a study of Leukocyte Adhesion Deficiency, is active but no longer recruiting, sponsored by Rocket Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene
Conditions Studied
Study Locations (3)
Other
- Hospital Infantil Universitario Niño Jesús - Madrid
- University College London Great Ormond Street Institute of Child Health (GOSH) - London
California
- University of California, Los Angeles (UCLA) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2036-10-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06282432
The ClinicalTrials.gov registry entry for NCT06282432 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rocket Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukocyte Adhesion Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT06282432 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT06282432 about?
NCT06282432 is a clinical study titled "Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)". This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene
What is the current status of trial NCT06282432?
This trial is currently active not recruiting. The enrollment target is 9 participants. The study started on 2022-03-09. Estimated completion is 2036-10-04.
What conditions does trial NCT06282432 study?
This clinical trial studies the following conditions: Leukocyte Adhesion Deficiency.
Who is sponsoring clinical trial NCT06282432?
This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06282432 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukocyte Adhesion Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.